Actively Recruiting
Sickle Cell Kidney Biorepository
Led by University of Texas Southwestern Medical Center · Updated on 2026-04-13
800
Participants Needed
2
Research Sites
1318 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Kidney disease is a major cause of illness and death in people with sickle cell disease and sickle cell trait. Despite these concerning facts, we do not (1) have an in-depth understanding of how kidney disease starts in sickle cell disease and sickle cell trait, (2) have detailed insights into why kidney disease is worse in people with sickle cell disease and sickle cell trait, (3) have management options that are tailored to treating or preventing kidney disease in people with sickle cell disease or sickle cell trait. The SCeK Biorepository is a specialized, secure repository designed for the collection of blood and urine samples from people with sickle cell disease and sickle cell trait. These samples are connected to detailed medical records, with the sole purpose of allowing researchers to better understand how kidney disease starts and progresses in people with the sickle cell gene. By studying these stored samples (using new tests) together with health information, researchers can find better early warning signs of kidney injury and develop better ways to protect kidney health in people with sickle cell disease and sickle cell trait.
CONDITIONS
Official Title
Sickle Cell Kidney Biorepository
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Estimated glomerular filtration rate greater than or equal to 15 mL/min
- Presence of any hemoglobinopathy confirmed by hemoglobin electrophoresis or genetic testing
- Controls without hemoglobinopathy may be selected if demographics match an enrolled participant with hemoglobinopathy
You will not qualify if you...
- Age 66 years or older
- Estimated glomerular filtration rate less than 15 mL/min or on dialysis
- Active pregnancy (may enroll 4 weeks or more after delivery)
- Active sickle cell pain episode requiring hospitalization, emergency room, or pain clinic visit (may enroll 2 weeks or more after severe pain resolution)
- Active malignancy on induction or consolidation treatment (maintenance chemotherapy in remission allowed)
- Prisoners
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Parkland Memorial Hospital
Dallas, Texas, United States, 75235
Actively Recruiting
2
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390
Actively Recruiting
Research Team
K
Kabir O Olaniran, MD, MPH, FASN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here